October 2025 – Hallbergmoos, Germany - Xpedite Diagnostics GmbH, a pioneer in accessible molecular testing technologies, announces the launch of SwiftX™ Sepsis (Research Use Only), a groundbreaking DNA extraction solution that isolates microbial DNA directly from primary whole-blood samples without the need for culture enrichment.
In sepsis research, sensitivity is everything, yet traditional workflows are challenged by the overwhelming abundance of human cells that mask scarce microbial signals. SwiftX™ Sepsis overcomes this barrier through a proprietary cell-capturing chemistry specifically optimized for binding microbial cells within whole blood. This breakthrough enables reliable recovery bacterial and fungal targets even at concentrations below 10 CFU/mL, accelerating molecular detection and pathogen profiling of blood stream infections from the very first sample.
SwiftX™ Sepsis extracts pathogen DNA from up to 10 mL of primary whole blood in under 45 minutes, transforming workflows that traditionally take days. Its cell-capture mechanism is optimized for concentrating bacterial and fungal target organisms before lysis, dramatically enhancing sensitivity and reproducibility. A subsequent heat-lysis and clearance step yields inhibitor-free DNA ready for PCR and qPCR, with less than 10 minutes of hands-on time and no need for centrifugation or spin columns.
Co-developed with academic and clinical partners, SwiftX™ Sepsis was validated on clinically relevant Gram-positive, Gram-negative, and fungal pathogens, including E. coli, K. pneumoniae, S. pneumoniae, P. aeruginosa, S. aureus, E. faecalis, and C. albicans. Initial studies demonstrated consistent recovery and reproducibility across all targets, with sensitivity reaching below 10 CFU/mL, depending on assay design and gene copy number.
“The true innovation in SwiftX™ Sepsis is our optimized microbial cell-capture chemistry,” said Dr. Andy Wende, Founder and Managing Director of Xpedite Diagnostics GmbH. “It favors binding of bacterial and fungal cells over binding to other signatures and cells in complex whole-blood matrices, giving researchers access to microbial DNA that would otherwise remain undetectable. This is a game-changer for culture-free sepsis and AMR research.”
Product Highlights
• Selective microbial cell capture for unparalleled sensitivity in high-background samples.
• Extract pathogen DNA from up to 10 mL of whole blood in less than 45 minutes.
• Detect bacteria and fungi directly from primary blood specimens, no culture required.
• Centrifuge- and column-free workflow, less than 10 minutes hands-on time.
• Yields inhibitor-free DNA for PCR and qPCR.
• Automation-ready, compatible with bench-top liquid handlers and SwiftXtractor™.
• Environmentally responsible, no hazardous solvents.
SwiftX™ Sepsis bridges the gap between molecular research and translational diagnostics, providing a powerful, culture-free tool for sepsis, host–pathogen interaction and AMR research. By combining microbial selectivity with workflow simplicity, it enables high-fidelity DNA extraction even from one of the most complex sample types — whole blood.
Product Availability
SwiftX™ Sepsis (RUO) is now available for purchase and includes all necessary reagents for pathogen DNA extraction from up to 10 mL of whole blood. For detailed product specifications, validation data, and ordering information, contact Xpedite Diagnostics or visit the product page at www.xpedite-dx.com.
About Xpedite Diagnostics GmbH
Xpedite Diagnostics GmbH is a German biotechnology company advancing rapid, reliable, and sustainable nucleic acid extraction technologies. With a growing portfolio of CE-IVD and RUO products, Xpedite enables fast, field-deployable molecular workflows for diagnostics, environmental testing, and life science research worldwide.